Guidelines on Radioisotope Treatment of Bone Metastases in Prostate Cancer

Radium-223 (Ra-223), strontium-89 (Sr-89), and samarium-153 (Sm-153) are radiopharmaceuticals approved in the United States and elsewhere for the treatment of painful skeletal metastases in select populations (Tables 30.1 and 30.2). The primary aim of this chapter is to provide a cohesive educational review of practice recommendations for these agents using guidelines from professional societies, prescribing information, and published observations.